Search
Firuglipel
go.drugbank.com/drugs/DB19506InvestigationalFiruglipel has a monoisotopic molecular weight of 467.19 Da. … Firuglipel is under investigation in clinical trial NCT02647320 (12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin).
Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB21765ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/West Virginia/30/2022 (H1N1) Recombinant Hemagglutinin Antigen
go.drugbank.com/drugs/DB17995ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Georgia/12/2022 CVR-167 (H1N1) Antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB17996ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Victoria/4897/2022 IVR-238 (H1N1) Antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB17998ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB18661ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Sydney/1304/2022 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB19321ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Massachusetts/18/2022 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB19322ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB19323ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Thailand/8/2022 IVR-237 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB19324ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.